The biopharma distance is a tough nut. A company may implode on one product's clinical trial collapse or burst on precisely the same news; that therapies/drugs have not promise but profitable promise is a craphshoot. However, here is a couple to watch on:
It has been brutalized since the start of the year and also the last earnings statement was disappointing than expected. When you examine the weekly, you will notice that there's not just space for an explosion to the upside, but also total implosion, a la VRX, that's another one to see:
That rebound in the end looks like a dead bounce, therefore there might be further weakness ahead (that is why I am not yet diving into that pool).